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ABSTRACT
Background: Since the observation that Bacillus
Calmette–Guérin (BCG) vaccination in children corre-
lates with a decreased prevalence of asthma, several
investigators have been attempting to reproduce this
effect experimentally in mouse models of asthma.
While these reports have agreed in some areas, uncer-
tainty has remained as to the effect of BCG on IgE
and asthmatic response in general. Furthermore, the
effect of mycobacterial antigens on the early allergic
response and the release of bronchoconstrictory medi-
ators have not been examined. In the present study, 
we have aimed to more completely describe the effect
of BCG and Mycobacterium vaccae on early and
late allergic responses (EAR and LAR, respectively),
airway hyperresponsiveness (AHR) and broncho-
constrictory mediators in the mouse model of allergic
airway inflammation.
Methods: Using BALB/c mice sensitized to ovalbumin
(OVA) and treated twice with either BCG or M. vaccae
(1 × 105 CFU, intranasally), we investigated airway
resistance of both the EAR and LAR, AHR to metha-
choline, serum total and antigen-specific IgE, cysteinyl
leukotrienes in bronchoalveolar lavage (BAL) fluid
(10 min following challenge), a complete cell differen-
tial of the BAL (24 h post-challenge), BAL and serum
cytokines and lung histology.
Results: Neither BCG nor M. vaccae were able to
attenuate the EAR, yet both were able to abrogate the
parameters used to evaluate the LAR. Interestingly, in
neither case were serum or OVA-specific IgE levels
reduced after treatment with mycobacterial antigens
and type 1/type 2 T cell cytokine skewing, based on
cytokine levels in BAL and serum, was incomplete.
Conclusions: These results have led us to conclude
that the mycobacterial antigens elicit potential anti-
asthmatic effects independent of changes in IgE levels.
We speculate that mycobacteria likely directly or indi-
rectly suppress eosinophil effector function via attenu-
ation of type 2 T cell-mediated immune responses.
Key words: airway hyperresponsiveness, asthma,
Bacillus Calmette–Guérin, eosinophils, IgE, Myco-
bacterium vaccae.
INTRODUCTION
Allergic bronchial asthma is a disease characterized by
the manifestation of occluded airways, accounted for by
smooth muscle hyperresponsiveness, mucus plugging
and airway wall edema, elevated serum IgE concentra-
tion and inflammatory cell recruitment into the lungs con-
sisting notably of eosinophils. These signs and symptoms
are also known to occur amidst a cytokine milieu com-
posed of increased concentrations of interleukin (IL)-4, 
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IL-5 and IL-13, which are classified as type 2 T cell
cytokines.1 These cytokines are able to promote IgE pro-
duction (IL-4),2 stimulate the growth and differentiation of
eosinophils (IL-5)3 and promote mucus hypersecretion
(IL-13).4 A different group of cytokines has been corre-
lated with the non-atopic state. These include interferon
(IFN)-γ and IL-12; the former being classified as a type 1
T cell cytokine.1,5 Importantly, these two groups of cyto-
kines have been suggested to regulate the development
and function of each other.6,7 Research has been directed
on the one hand at more fully understanding how some
cytokines promote allergic diseases, such as asthma,
and, on the other, at how an increased ratio of type 1 to
type 2 T cell cytokines may be able to alleviate or even
prevent these diseases.
Since the publication of the epidemiological study by
Shirakawa et al.8 that showed an inverse correlation
between delayed-type hypersensitivity and IgE titers in
Japanese school-aged children, much attention has been
directed towards mycobacterial exposure and its relation-
ship to asthma. Bacillus Calmette-Guérin (BCG) is a
mycobacterial preparation that has been used for many
decades as a vaccine for tuberculosis. This potent stimu-
lator of cell-mediated immunity and, thus, type 1 T cell
cytokines has also shown effects against certain types 
of bladder cancer.9 This history has made BCG (and, to 
a lesser extent, other mycobacterial species, such as
Mycobacterium vaccae) an ideal candidate for testing the
hypothesis that Th1-favoring adjuvants can attenuate
asthma both in animal models and humans.
Indeed, research with the mouse model of asthma has
shown consistently positive data for the capacity of
various preparations of mycobacterial antigens to 
prevent allergic sensitization.10–15 Recently, Erb et al.16
administered BCG either intranasally or intraperitoneally
and found significant suppression in the bronchoalveolar
lavage (BAL) fluid eosinophilia, mirrored in the case of
intranasal infection with decreased concentration of local
IL-5 production. Research investigating the relationship
between BCG and asthma in a mouse model has
reported conflicting results in terms of serum IgE, a key
trigger for mast cell degranulation and the early allergic
response. Herz et al.11 observed results similar to Erb 
et al.16 with intravenous BCG delivery, including suppres-
sion of eosinophilia and type 2 T cell cytokines. However,
these effects were found in conjunction with marked sup-
pression of IgE production. This is in contrast with other
investigations,14,16 where no effect of BCG on IgE, either
total or antigen specific, was observed. This discrepancy
could be due to differences in the protocols and treat-
ments with BCG and/or M. vaccae. Furthermore, to our
knowledge, there is no study comparing the effect of
BCG on IgE and EAR.
We, for the first time, present a complete picture of the
effect of mycobacterial antigens on both the early and late
allergic responses (EAR and LAR, respectively), airway
hyperresponsiveness (AHR) and key cytokines, as well as
serum total and antigen-specific IgE. Furthermore, this is
the first report of the effects of BCG administration on two
potential mediators of the EAR, namely leukotrienes and
histamine. It was our hypothesis that mycobacterial anti-
gens suppress the EAR, LAR and AHR by attenuating
antigen-specific IgE, the release of potent bronchospastic
mediators and cytokines relevant to asthma.
METHODS
Animals
Six-week-old male BALB/c mice were obtained from
Harlan Laboratories and housed according to National
Institutes of Health guidelines. Mice were housed under
pathogen-free conditions in separate cages according to
treatment, with no more than five mice per cage. Food
and water were provided ad libitum. The research proto-
col of this study was approved by the Animal Research
Committee of Creighton University.
Sensitization and immunization
Mice were sensitized on days 0 and 14 with an intraperi-
toneal injection of 20 µg grade V chicken egg ovalbumin
(OVA; Sigma-Aldrich, St Louis, MO, USA) and 2 mg
alum (Imject Alum; Pierce, Rockford, IL, USA) suspended
in phosphate-buffered saline (PBS) to a total volume of
100 µL. Non-sensitized control animals received only the
PBS and alum. Daily, from day 21 through to day 23,
mice were exposed to nebulized 2% OVA for 20 min.
Lyophilized BCG (Tice; Organon, West Orange, NJ,
USA) and M. vaccae (ATCC #29678) were cultured in
Lowenstein–Jensen media (Remel, Lenexa, KS, USA) at
the Creighton University Pathology Laboratory. Three to 
4 weeks after the cultures were begun, the vials were cen-
trifuged at 900 g for 15 min at 4°C and resuspended in
PBS. Logarithmic dilutions of the cells into sterile vials
were made for both bacteria. Seven-H10 Agar plates
(Remel) corresponding to logarithmic dilutions were incu-
bated for an additional 2 weeks. Stock vials were frozen
in the meantime at –80°C. Colony forming units (CFU)
on the culture plates were counted and an estimation of
the number of viable organisms in the stock vials was
then made. Aliquots of 1 × 105 organisms (50 µL) in
media were made and refrozen at –80°C until needed.
Treatment groups
Mice in experimental groups were anesthetized with 
40 mg/kg ketamine and 2 mg/kg xylazine (20 : 1) 
followed by immunization with 1 × 105 CFU of the appro-
priate organism via the intranasal (i.n.) route. Non-
sensitized and sensitized control mice were treated only
with vehicle (PBS). The first immunization was administered
on day –7 (7 days prior to the start of sensitization) and 
a booster dose of equal size was administered on day 17.
Non-invasive method for measuring 
pulmonary function
Single-chamber whole-body plethysmographs (Buxco
Electronics, Troy, NY, USA) were used to measure pul-
monary functions.17 This method has been demonstrated
to accurately reflect airway resistance by us18 and
others.19,20 For comparison purposes, the results of metha-
choline challenges were also expressed in terms of a PC200,
the dose of methacholine at which a 200% increase in
enhanced pause (Penh) units was observed. The results of
antigen challenges are expressed as the area under the
curve (AUC). The AUC is a measure of pulmonary resis-
tance measured in Penh units as a function of time within the
first 15 min (EAR) and between 1 and 6 h (LAR). Here, an
individual mouse’s baseline Penh value serves as the refer-
ence to which subsequent increases in Penh are compared.
Allergen challenge
All mice were placed in individual plethysmograph cham-
bers on day 25 and baseline Penh readings were taken.
Challenge to 2% OVA lasting for 5 min followed. For
some animals, this was followed by recording of pul-
monary functions during the EAR (0–15 min) and the 
LAR (1–6 h), methacholine challenge and collection of
tissues. Others were killed 10 min following antigen chal-
lenge, without pulmonary function recording, for collec-
tion of BAL fluid only.
Methacholine challenge
Mice were challenged on day 26, 24 h post-final OVA
challenge, with increasing doses of methacholine and
pulmonary functions were recorded using the Buxco
whole-body plethysmograph system. An aerosol chal-
lenge at each dose was administered via an Ultra 
Neb-99 (DeVilbiss, Sommerset, PA, USA) with the highest
setting for exactly 1 min. A 1 min washout period fol-
lowed. Immediately thereafter, data were recorded for 
5 min and a mean of this time period, in terms of Penh,
was calculated. After the recording period, the Penh values
for each mouse were allowed to return to baseline before
the next higher dose of methacholine was administered.
Bronchoalveolar lavage and tissue collection
Immediately following the methacholine challenge, mice
were killed with a lethal dose of pentobarbital. Tracheas
were cannulated and lungs were washed with PBS and
BAL fluid was collected. Cytospin slides were prepared
from each BAL sample following cell counting using a
Coulter counter. Slides were stained with Diff-Quik
(Baxter Healthcare, McGaw Park, IL, USA) for analysis of
differential cell populations. Whole lungs were removed,
set in tissue-freezing medium (Triangle Biomedical
Sciences, Durham, NC, USA) and frozen immediately in
liquid nitrogen. Seven to 8 µm sections were prepared
and stained with either hematoxylin and eosin (H&E) or
with Ziehl–Neelsen for acid-fast bacteria.
Histamine and cysteinyl leukotrienes
Mice were killed 10 min following OVA challenge on day
25 and BAL fluid was collected. Aliquots from each
mouse were pooled and supernatants were collected
following centrifugation at 900 g for 15 min at 4°C.
Supernatants from each mouse (approximately 3 mL)
were concentrated down to 1 mL at –20°C. This pro-
cedure does not affect the recovery of histamine, leuko-
trienes or cytokines. Commercially available ELISA kits 
for histamine (Research Diagnostics, Flanders, NJ, USA)
and cysteinyl leukotriene (CAST; American Laboratory
Products, Windham, NH, USA) were used according to
manufacturers’ recommendations. Assay sensitivities for
histamine and cysteinyl leukotriene were 2.7 ng/mL and
100 pg/mL, respectively.
Cytokine analysis
Cytokines were measured in the supernatants of BAL fluid
collected from either the group of animals killed 10 min
after OVA challenge or 1 day after OVA challenge. Anti-
body pairs for IL-4, IL-5 and IFN-γ, as well as standards
(Pharmingen, San Diego, CA, USA), were used according
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to the manufacturer’s recommendations. Assay sensitivi-
ties for IL-4, IL-5 and IFN-γ were 5, 5 and 10 pg/mL,
respectively.
Serum immunoglobulin analysis
Blood collected after animals had been killed on day 26
was immediately centrifuged at 900 g for 15 min at 4°C
and serum was collected and stored at –70°C for later
analysis. An ELISA for both total and antigen-specific IgE
in all samples was conducted in the same ELISA plate as
described previously21 and according to manufacturer’s
recommendations using rat antimouse IgE (Pharmingen),
standard IgE (Pharmingen) and rat antimouse IgE-HRP
(Southern Biotechnology Associates, Birmingham, AL,
USA) for the total IgE assay, with the substitution of
biotinylated ovalbumin (Immunoprobe Biotinylation Kit;
Sigma), followed by addition of streptavidin–horseradish
peroxidase (HRP; Pharmingen), for the antigen-specific
assay. Both cytokine and immunoglobulin assays were
developed with 3,3′,5,5′-tetramethyl benzidine (TMB)
substrate and read at 450 nm using a Bio-Rad (Hercules,
CA, USA) microplate reader and software. Sensitivity for
total IgE was 1 ng/mL. Antigen-specific IgE results are
expressed in units of absorbance (optical density; OD).
Statistical analysis
Data were analyzed using GraphPad PR ISM (GraphPad
Software, San Diego, CA, USA) statistical analysis and
graphing software. Whenever suitable, results were inter-
preted using analysis of variance (ANOVA) test with Tukey’s
post hoc test or Student’s t-test. Differences were consid-
ered statistically significant when P < 0.05.
RESULTS
Bacillus Calmette–Guérin and M. vaccae
treatment substantially attenuates airway
resistance associated with LAR without 
affecting EAR
An EAR was observed in sensitized animals within 0–2 min
and resolved by 15 min. While sensitized control mice
exhibited a significant EAR, neither the BCG- nor the 
M. vaccae-treated mice appeared to exhibit significant
protection at all from this immediate response (Table 1).
However, a dramatic difference was seen during the LAR,
which began at approximately 1 h post-OVA challenge
and continued through to 6 h. Here, the sensitized control
mice continued to show very significant responses. Yet,
both the BCG- and M. vaccae-treatment groups showed
abrogation of airway resistance associated with the LAR
(Table 1).
Immunization with BCG and M. vaccae 
completely suppressed AHR to methacholine
Mice receiving intranasal BCG or M. vaccae showed 
significant (P < 0.01) protection against AHR at every con-
centration of methacholine used in this experiment (Fig. 1).
The results of the methacholine challenge were also
expressed in terms of the dose at which a 200% increase in
Penh units from baseline is reached (PC200). Mice treated
with BCG required five- to sixfold more methacholine 
(P < 0.01) than the untreated OVA-sensitized controls 
in order to reach the PC200, while those treated with 
M. vaccae were protected more so with seven- to eightfold
more methacholine required compared with the untreated
OVA-sensitized controls (Table 1).
Bacillus Calmette–Guérin and M. vaccae
treatment suppress BAL fluid eosinophilia
Near complete abrogation of total BAL eosinophil
numbers was observed in both treatment groups (60.8 ±
20 × 103 cells for BCG; 50 ± 15 × 103 cells for 
M. vaccae; 462 ± 47 × 103 cells for sensitized controls;
and none for non-sensitized controls; P < 0.001 for both
treatments compared with sensitized control), while other
cell populations were not affected compared with those
of the sensitized control mice (data not shown). Total cell
counts in the BAL were also reduced (490 ± 96 × 103
cells for BCG; 399 ± 70 × 103 cells for M. vaccae;
1160 ± 75 × 103 cells for sensitized controls; P < 0.01)
with either bacterial inoculation.
Treatment with BCG or M. vaccae does not
decrease either total serum IgE or 
OVA-specific IgE
Treatment with two doses of BCG or M. vaccae during the
sensitization procedure resulted in an apparent boost of
IgE production. Mean IgE concentrations in BCG- and
M. vaccae-treated mice were 1.5- to twofold (respec-
tively) of those found in sensitized control mice (Table 2),
while failing to reach significance. This was also the case
in terms of OVA-specific IgE, where there was no difference
seen in the treated groups compared with the sensitized
controls (Table 2).
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Table 1 Effect of mycobacterial antigens on pulmonary functions
Study groups AUC (arbitrary units) PC200 to methacholine
EAR (0–15 min) LAR (1–6 h) (mg/mL)
Non-sensitized 0.57 ± 0.2** 3.3 ± 1.4*** 23.6 ± 2.3**
Sensitized 2.7 ± 0.7 52.9 ± 5.8 3.8 ± 1.2
Bacillus Calmette–Guérin 2.5 ± 0.7‡ 16.0 ± 4.1***† 29.8 ± 4.5**
Mycobacterium vaccae 2.0 ± 0.2‡ 6.8 ± 3.9*** 41.2 ± 5.7**†
Mice were sensitized, treated and challenged as described in Methods. The area under the curve (AUC) of both the early allergic response (EAR)
and late allergic response (LAR) and PC200 to methacholine (see Methods) were calculated for each animal.
Data are the mean±SEM for eight animals per group. Significant differences between the groups were determined using ANOVA. **P < 0.01, 
***P < 0.001 compared with sensitized controls; †P < 0.05; ‡P < 0.001 compared with non-sensitized controls.
Fig. 1 Effect of mycobacterial treatment on airway hyperresponsiveness to methacholine. Groups of mice were sensitized to oval-
bumin (OVA; except the non-sensitized controls) and treated with either vehicle (phosphate-buffered saline; PBS), Bacillus
Calmette–Guérin (BCG) at 1 × 105 CFU (2×) intranasally or Mycobacterium vaccae (2×) at 1 × 105 CFUs intranasally. Twenty-four
hours following OVA challenge, mice were placed into individual barometric plethysmograph chambers and exposed to increasing
concentrations of nebulized methacholine in PBS. The Penh index refers to fold-increase over baseline enhanced pause (Penh) readings
for each individual animal. (a) The BCG-treated animals () showed significant suppression of airway hyperresponsiveness (AHR) at
each dose administered. (b) The M. vaccae-treated animals () showed very similar, significant suppression of AHR. Data are the
mean±SEM for eight animals in each group with comparisons with sensitized control animals (*P < 0.05, **P < 0.01) or non-
sensitized control animals (no difference). (), non-sensitized control; (), OVA sensitized and challenged.
Table 2 Effect of mycobacterial antigens on total and ovalbumin-specific serum IgE concentrations
Study groups Total IgE (ng/mL) OVA-specific IgE (OD)
Non-sensitized ≤ 100 0
Sensitized 425 ± 70 0.7 ± 0.2
Bacillus Calmette–Guérin 777 ± 269 1.6 ± 0.8
Mycobacterium vaccae 1015 ± 256 1.2 ± 0.7
Mice were sensitized and treated as described in Methods. Serum antibody production for ovalbumin (OVA)-specific and total serum IgE levels
was determined using standard ELISA.
Data are the mean±SEM for eight animals per group. No significant differences among the sensitized and sensitized/treated groups were
observed using ANOVA.
Histamine was not determined to be a 
significant EAR mediator in this model
In some experiments, mice were sensitized, treated with
either bacteria and challenged (as described in Methods),
yet killed 10 min following OVA challenge for collection
and analysis of potential EAR mediators present in BAL
fluid. Histamine levels were assayed and found not to be
present in differing amounts among the treatment or
control groups (Table 3).
No suppression of the cysteinyl leukotrienes
was seen after treatment with either BCG or
M. vaccae
Bronchoalveolar lavage fluid collected 10 min after OVA
challenge was also analyzed for leukotriene content
during the EAR. Leukotriene assays showed significantly
increased amounts (P < 0.05) of the cysteinyl leuko-
trienes LTC4, LTD4 and LTE4 in OVA-sensitized and chal-
lenged mice compared with non-sensitized control
mice (Table 3). Leukotriene levels were elevated in both
treatment groups compared with the sensitized controls,
although this was not statistically significant.
Bacillus Calmette–Guérin-treated mice
showed increases in both type 1 and type 2
cytokines during the EAR
Bronchoalveolar lavage supernatants from the EAR were
also analyzed using ELISA for the presence of IL-4, IL-5
and IFN-γ levels. As expected, IFN-γ levels in the BAL
fluid of BCG-treated mice were significantly increased.
Interestingly, levels of IL-4 were also found to be signifi-
cantly higher than in sensitized control mice (Table 3).
Data were unavailable for M. vaccae-treated mice.
Bronchoalveolar lavage cytokines collected
after the LAR exhibited partial type 1/type 2
cytokine skewing
Bronchoalveolar lavage performed following metha-
choline challenge showed significantly decreased levels
of IL-5 for both BCG- and M. vaccae-treated mice, while
there was no significant difference in IL-4 concentrations
between the groups. Interferon-γ levels for both BCG-
and M. vaccae-groups were increased significantly com-
pared with sensitized controls (Table 4).
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Table 3 Effect of mycobacterial antigens on bronchoalveolar lavage mediators during the early allergic response
Histamine CysLTs IL-4 IL-5 IFN-γ
(ng/mL) (ng/mL) (pg/mL) (pg/mL) (pg/mL)
Non-sensitized 6.6 ± 1.3 ≤ 1 ≤ 5 ≤ 5 ≤ 10
Sensitized 5.5 ± 0.5 3.9 ± 1.7 21.3 ± 1.3 ≤ 5 ≤ 10
Bacillus Calmette–Guérin 5.6 ± 0.2 8.0 ± 1.1 30.6 ± 3.3* ≤ 5 37.2 ± 7.8*
Mycobacterium vaccae 6.2 ± 0.9 8.1 ± 2.3 ND ND ND
Mice were sensitized and treated as described in the Methods. Bronchoalveolar lavage (BAL) was performed 10 min following ovalbumin chal-
lenge and supernatants were analyzed using ELISA.
Data are the mean±SEM for for five animals per group. *P < 0.05 compared with sensitized controls (ANOVA).
CysLTs, cysteinyl leukotrienes; IL, interleukin; IFN-γ, interferon-γ; ND, data unavailable.
Table 4 Effect of mycobacterial antigens on bronchoalveolar lavage and serum cytokines after the late allergic response
Bronchoalveolar lavage Serum IL-5
IL-4 (pg/mL) IL-5 (pg/mL) IFN-γ (pg/mL) (pg/mL)
Non-sensitized ≤ 10 ≤ 5 ≤ 10 145.3 ± 34.6
Sensitized 87.8 ± 14.7 90.9 ± 19.0 81.5 ± 1.3 410.2 ± 217
Bacillus Calmette–Guérin 62.8 ± 7.9 15.9 ± 19.1* 145.0 ± 19.0* 608 ± 198
Mycobacterium vaccae 74.9 ± 13.1 23.6 ± 4.4* 158.8 ± 24.4* 725.6 ± 201†
Mice were sensitized and treated as described in Methods. Bronchoalveolar lavage supernatants and serum were analyzed with paired antibodies
using ELISA.
Data are the mean±SEM for for five animals per group. Statistical significance among the groups was determined using ANOVA. *P < 0.05 
compared with sensitized controls; †P < 0.05 compared with non-sensitized controls.
IL, interleukin; IFN-γ, interferon-γ.
Serum concentrations of IL-5 collected after
the LAR were unaffected
To determine local versus systemic effects of intranasal
mycobacteria treatment, serum samples were also ana-
lyzed for the presence of IL-5 using ELISA. No differences
in IL-5 levels were observed among any of the groups
(Table 4).
Histology
Marked edema and inflammatory infiltration were seen 
in H&E-stained lung sections from OVA-sensitized
control animals (Fig. 2a). Lungs of the BCG- (Fig. 2b)
and M. vaccae-treated (Fig. 2c) mice showed an absence
of inflammation and only mild edema. Bronchoalveolar
lavage fluid cell samples were also stained with Ziehl–
Neelsen stain for acid-fast bacilli. Slides from BCG-
treated mice showed macrophages repleted with acid-
fast bacilli (Fig. 2d). Lung sections were negative for
acid-fast bacilli in all cases.
DISCUSSION
Several groups of investigators, in addition to data from
our laboratory, have previously shown a suppressive
effect of BCG or M. vaccae immunization on BAL
eosinophilia,10,11,16,17 AHR (ex vivo)11,17 and (selectively)
type 2 cytokines10,11,16,17,22 in a mouse model of asthma.
IgE production, has been variable, with some studies
showing suppression10,11,22 and another showing no dif-
ference,16 while several other studies have shown both
effects, depending on mouse gender or characteristics of
the mycobacteria.13,14 We designed the present study to
more closely investigate the effect of mycobacterial anti-
gens on parameters of both the EAR and LAR. This is the
first report of several of these outcome parameters in
BCG- or M. vaccae-treated, sensitized mice.
There is now mounting evidence that the presence of
immune modulators, such as BCG, in the airways and/or
the concurrent presence of allergen more effectively influ-
ence cytokine production, type 1/type 2 T cell balance
and, thus, the degree of allergic inflammation. Erb et al.16
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Fig. 2 Histologic staining of
inflammatory cells from lung
sections and bronchoalveolar
lavage sample. (a) Lung section
from a sensitized control animal
stained with hematoxylin and
eosin (H&E; original magnifi-
cation ×10). (b) Lung section
from a Bacillus Calmette–Guérin
(BCG)-treated animal stained
with H&E (original magnification
×10). (c) Lung section from a
Mycobacterium vaccae-treated
animal stained with H&E (original
magnification ×10). (d) Broncho-
alveolar lavage cells stained with
Ziehl–Neelsen (original magnifi-
cation ×100). The arrow points
to an acid-fast bacilli-laden
macrophage contacting a lym-
phocyte.
observed that intranasal BCG infection had no effect on
blood eosinophilia and that only minor BAL eosinophilia
could be restored with intranasal recombinant IL-5 (rIL-5)
treatment. Although these authors found lesser protection
in BAL eosinophilia with other routes of BCG infection,
the presence of blood eosinophils or the ability of rIL-5 
to restore BAL eosinophilia with other routes was not 
discussed. Sano et al.15 have done substantial work that
supports the notion that antigen-presenting cells can
most effectively modulate the specific response of T cells
when armed with both allergen (OVA) and immune mod-
ulator (mycobacteria) at the same time.
The results of our cytokine analyses after intranasal
mycobacteria delivery suggest two conclusions. First,
changes in BAL IL-5 following the LAR did not extend to
the periphery, with serum levels of this cytokine remaining
statistically unchanged. This suggests that the eosinophil/
IL-5 effects of intranasal treatment with BCG remain
restricted to the local environment, which has also been
presented by others.16 That peripheral BCG introduction
was still able to affect anti-asthmatic changes in the
lung10,11 may reflect both a disseminated infection and
the fact that this model of sensitization involves a stage of
lung-specific sensitization and/or challenge. Further sup-
porting this conclusion were the unaffected serum IgE
concentrations, a finding also recorded by Erb et al.16
Second, IL-4, in addition to IgE, does not appear to be
a necessary target for mycobacteria modulation in order
to confer the protection from AHR to methacholine, BAL
eosinophilia and OVA-specific airway resistance associ-
ated with the LAR. This cytokine was found to be sig-
nificantly increased in EAR BAL fluid and statistically
unchanged in BAL fluid recovered after the LAR. This
failure to suppress IL-4 may further account for the failure
of either mycobacterial species to suppress the parame-
ters we used to evaluate the EAR. Others investigating 
IL-4 from splenocyte sources following in vivo BCG
administration have made similar observations.10,11
Indeed, BALB/c mice expressing the bcgs allele produced
increased elevated levels of IL-4, an effect that did 
not confer disadvantages in controlling BCG growth.23
Mycobacterium vaccae was observed to suppress IL-4
from splenocyte cultures at only one of three doses
(several log units higher than ours) in another experi-
ment,22 the sensitization/treatment kinetics of which differ
greatly from ours. Interleukin-4 is also known to enable
the recruitment of eosinophils through the induction of
cell-adhesion molecules and the potent chemokine for
eosinophils eotaxin.24,25 It is tempting to speculate that
suppression of other chemokines, in addition to IL-5, may
have accounted for a potential ability to override the
capabilities of IL-4. Further investigation is needed.
Interferon-γ, also measured in BAL fluid in the EAR, was
observed to be significantly increased for BCG-treated
mice in both cases and M. vaccae-treated mice in the
latter case. This cytokine, a potent inducer of type 1 T cell
responses, may account for some of the advantages in
this model. Knockout mice sensitized and treated with
BCG showed partial, albeit incomplete, protection
against airway eosinophilia.16
A clear picture of the specific roles for various mast cell
mediators that contribute to bronchoconstriction in mice
has yet to be drawn. In guinea pigs, a leukotriene recep-
tor antagonist eliminated both early and late phase
airway resistance,26 yet, in mice, the 5-lipoxygenase
inhibitor zileuton prevented some parameters of the
asthmatic response, but not AHR.27 It is known that
leukotrienes are 100- to 1000-fold more potent than
histamine in affecting airway function,28 yet a similar dif-
ferential physiological effect in the mouse model is not
apparent. Some reports of histamine antagonists offering
limited protection on AHR29 exist, while others found
neither histamine nor LTC4 able to induce much increase
in airway resistance in vitro.30 5-Hydroxytryptamine and/
or endothelin-1 may be more important inducers of the
early phase bronchoconstriction in mice.30 Interestingly,
in our model, we found no difference in BAL histamine
concentrations among the groups. Furthermore, given
the reports mentioned above, it may not be surprising
that the elevated leukotriene concentrations (albeit,
insignificantly so) found in our sensitized/treated animals
did not translate into dramatic increases in the EAR as
measured using barometric plethysmography.
This is not the first report of live mycobacteria failing to
decrease serum IgE concentrations in sensitized mice.
Bakir et al.14 found that administration of live BCG
(subcutaneous) to newborn mice (104 CFU, one dose)
resulted in no decrease in serum IgE. In fact, a group of
animals receiving BCG compared with a group receiv-
ing only BCG diluent narrowly missed significance 
(P = 0.063).14 Interestingly, administration of killed BCG
did confer protection against IgE.14 Tükenmez et al.13
found that gender was a determining factor for dec-
reased IgE after treatment with killed BCG (intraperi-
toneal) in their model: male mice received no protection
while female mice did. The studies of Bakir et al.14 and
Tükenmez et al.13 may or may not conflict, because no
mention was made of gender in the former study. When
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BCG and M. vaccae were administered in combination in
the latter study (for a total of 1010 or 1012 CFU, depend-
ing on interpretation) significant reduction of IgE was
observed, regardless of gender.13 However, the introduc-
tion of such high numbers of bacteria in such small
animals may make the finding less impressive. Unfor-
tunately, in neither study were other parameters of aller-
gic sensitization examined, leaving few studies available
to examine the more complete impact of BCG or 
M. vaccae on a sensitized system. Erb et al.16 reported
failure of BCG to inhibit OVA-specific IgE, IgG1 and
IgG2a titers in their model. They also found no peripheral
changes in terms of eosinophilia, while finding suppres-
sion at the local site of BCG administration, within the
lungs. This could argue that intranasal inoculation with
BCG produced benefits limited to the intended location.
A more complete comparison of local and systemic
cytokine levels could help to answer this. Even a fourth
route of inoculation, intravenous, was used by Herz 
et al.,11 who were the first of only two groups to show sup-
pressed IgE and IgG1 titers with live BCG inoculation
(106 CFU, one dose). The team of Yang et al.10 achieved
similar results with one-dose intravenous administration
of 106 CFU BCG. Interestingly, although the background
strain differed in these experiments, only female mice
were used in either case, reminiscent of the results
achieved by Tükenmez et al. 13 In addition, it may be that
direct introduction of live BCG into the blood stream is
far more potent in its ability to modulate peripheral
immunoglobulin titers. Finally, in striking contrast to
our findings, Wang and Rook22 found significant pro-
tection against total IgE (but not OVA-specific IgE) after 
M. vaccae treatment. We speculate that these differences
lie in the higher bacteria load, the gender of the mice and
the heat-killed nature of the bacteria, as supported by the
preceding discussion.
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Fig. 3 Hypothetical target points for mycobacterial antigens in sustaining the early allergic response (EAR) and abrogation of the
late allergic response (LAR). Results from our research suggest that the benefits conferred by mycobacteria likely take place after
cross-linking of IgE receptors on mast cells but before eosinophil-effector function. Amidst concurrently unaffected or increased inter-
leukin (IL)-4 and early phase mediator production (1), there may be a suppression of chemokine and IL-5 production influencing the
capacity of eosinophils to accumulate in the lung (2). Mycobacteria may have direct or indirect suppressive effects on eosinophils (or
basophils) themselves (3), including an inhibition of cell adhesion molecules, specifically vascular cell adhesion molecule-1, neces-
sary for transmigration or stimulation of apoptosis. Interleukin-18 production from mycobacteria-laden macrophages or type 2
cytokine production from NK+ cells may promote a mixed type 1/type 2 T cell response (4). Interleukin-5, from several potential
sources, is locally suppressed (5). +, induction; x, suppression; CysLTs, cysteinyl leukotrienes; MC, mast cell; Eos, eosinophil; Bas,
basophil; Tc, cytotoxic T cell; DC, dendritic cell; IFN-γ, interferon-γ.
We found increased serum IgE, increases in both BAL
leukotrienes and specific airway resistance during the first
15 min following antigen challenge in treated mice that
were not significantly different from the sensitized control
group. The results from these mice, treated twice intra-
nasally with 105 CFU live BCG, indicate that the EAR is
not suppressed with mycobacteria treatment.
The LAR has been positively correlated with BAL
eosinophilia by several investigators.20,31 The blockade of
these cells has also been shown to prevent AHR.32 In our
experiments, suppression of airway resistance during this
period was very significant compared with the sensitized
controls. Strongly supporting this observation were the
dramatic decreases in BAL eosinophils and suppression
of AHR to methacholine, both in mycobacteria-treated
animals.
The notion of discordance between the EAR and the
LAR in mice is not without precedent.33 Hogan et al.34
showed a persistence of peribronchial and perivascular
eosinophil recruitment and AHR to methacholine in 
IL-4 –/– mice, devoid of OVA-specific antibodies of
several classes. Only in mice treated with blocking 
antibodies to IL-5 were eosinophilia and AHR sup-
pressed.32,34 Others have observed discordance between
IgE and AHR in mouse models,21,35,36 with conflicting
conclusions on the relationship between AHR and
eosinophilia.21,36 Some disagreement can be explained
when considering strains, sensitization and analysis
methods. Yet the true status is most certainly more
complex than we currently understand.
While supporting our overall observation of a discon-
nection between early and late responses, previously
published results seem to show the reverse of what we
observed in mycobacteria-treated animals, with mainte-
nance of the EAR and subsequent abrogation of the LAR.
A likely explanation for at least some of the differences is
linked to the idiosyncrasies of different background
strains (C57BL/6 mice were used in the study of Hogan 
et al.). Several authors have investigated the variable
degree to which factors such as IgE, AHR and eosin-
ophilia are present in various murine background
strains,37–39 as well as how the relationship among
various factors may depend on strain.35,40,41
With treatment of either of two mycobacterial species,
we showed near-complete abrogation of the LAR without
any suppression of the preceding EAR. The suppression
of AHR to methacholine was as impressive as that 
of the suppression of airway resistance specific to OVA
challenge, suggesting a common cause, the infiltrating
eosinophil, a conclusion supported by numerous
reports.3,20,31,32,42 However, what we observed was rather
interesting: increased serum IgE was present in sensitized
control mice along with BAL eosinophilia and AHR,
while BAL eosinophilia, as well as AHR, were absent 
in mycobacteria-treated mice despite the presence of
increased serum IgE. Our data support a hypothesis that
mycobacterial antigen treatment is somehow able to
short-circuit the cascade of events at a point after IgE
production and immediate mast cell degranulation but
before eosinophil-related deleterious effects, or poten-
tially those of another cell type. Possibilities may include
suppression of cytokine and/or chemokine production,
inhibition of cell adhesion molecules, specifically
vacular cell adhesion molecule-1, necessary for trans-
migration, stimulation of apoptosis, or a direct, sup-
pressive effect of mycobacteria on eosinophils themselves
(Fig. 3).
Taken together, these results indicate that mycobacterial
(both BCG and M. vaccae) administration in a mouse
model of asthma does not suppress early allergic
response, IgE and BAL leukotrienes, while abrogating
late-phase airway resistance to ovalbumin challenge,
BAL eosinophilia and AHR to methacholine. These find-
ings narrow the focus in searching for the mechanism(s)
through which mycobacteria may alleviate the symptoms
of asthma.
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